Tissue-Link modtager investering til udvikling af banebrydende blødningsstop-teknologi
Tissue-Link ApS har sikret sig yderligere finansiering til at optimere og videreudvikle deres innovative teknologi, der effektivt stopper blødninger, som ikke kan standses med de produkter, der findes på markedet i dag. Virksomheden har modtaget en investering fra Christian Nielsens Fond til at forbedre produktionsprocessen, som supplement til Grant fra Innovationsfonden.
Teknologien blev oprindeligt udviklet til militært brug, men testes nu også til kirurgiske procedurer på Rigshospitalet. Samtidig arbejder Tissue-Link med DTU og Bioneer på at gøre produktionsmetoden mere miljøvenlig, fleksibel og effektiv. Den videreudvikling af teknologien kan potentielt revolutionere kirurgisk behandling og forbedre patientplejen både nationalt og internationalt.
Tissue-Link Secures Funding to Advance Groundbreaking Hemostasis Technology
Tissue-Link ApS has secured additional funding to optimize and further develop its innovative technology, which effectively stops bleeding that cannot be controlled with currently available products. The company has received an investment from the Christian Nielsen Foundation to improve the production process, supplementing the grant from the Innovation Fund.
The technology was originally developed for military use but is now also being tested for surgical procedures at Rigshospitalet. At the same time, Tissue-Link is collaborating with DTU and Bioneer to make the production method more environmentally friendly, flexible, and efficient. The development of the technology has the potential to revolutionize surgical treatment and improve patient care both nationally and internationally